Irreversible electroporation in combination with immune checkpoint inhibi-tion , in patients with metastatic pancreatic cancer - A prospective, phase 2 study
Latest Information Update: 16 Oct 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CHECKPOINT
- 13 Sep 2023 Status changed from recruiting to discontinued.
- 13 Sep 2022 Planned initiation date changed from 1 Sep 2022 to 14 Sep 2022.
- 13 Sep 2022 Status changed from not yet recruiting to recruiting.